The Impact of Drug Interactions with Tyrosine Kinase Inhibitors on Adverse Event Development based on the changes of drug concentration level: Meta-analysis
10.24304/kjcp.2024.34.1.71
- Author:
JinAh HWANG
1
;
Heeyoung LEE
Author Information
1. Department of Medicinal Biosciences, Konyang University, Nonsan, 32992, Republic of Korea
- Publication Type:Original Article
- From:Korean Journal of Clinical Pharmacy
2024;34(1):71-78
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Oral cancer drugs, particularly tyrosine kinase inhibitors (TKIs), are increasingly popular due to their convenience.However, they pose challenges like drug interactions, especially with medications like azole antifungals. While the FDA providessome guidance, more detailed information is needed to manage these interactions effectively. A meta-analysis was conducted tounderstand the impact of interactions between TKIs and azole antifungals on adverse events during clinical studies.
Methods:A meta-analysis followed PRISMA guidelines. Data from PubMed, EMBASE, and references were searched until November 30, 2021. Inclusion criteria encompassed studies on TKI-antifungal interactions in English. Study selection and quality assessment were conducted by two independent investigators.
Results:Out of 158 articles, 11 were selected for analysis. Combination therapy showed a slight increase in adverse events but was not statistically significant (OR 1.02, 95% CI 0.49-2.13, p=0.95). AUC and Cmax fold changes did not significantly impact adverse event development. Both itraconazole and ketoconazole showed no significant difference in adverse event development compared to TKI alone.
Conclusions:Study finds TKI-DDI not significantlylinked to AE increase; azole antifungal types not related to AE. Future DDI research crucial for drug development.
